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Alzheimer’s disease  is  an  intractable neurodegenerative disorder, characterized by the formation of  senile plaques and  neurofibrillary tangles (NFTs) which are the  
pathological hallmarks of the disease particularly in elder persons of age 65 and above. 
Beta-site APP cleaving enzyme (BACE-1) is an aspartyl protease, which initiates the processing of  amyloidogenic pathway and  is responsible  for the formation  
of   Senile plaques, a   causative agent  of the disease. 
Elevated level of BACE-1 causes the accumulation of insoluble form of Aβ peptides.  
Five published inhibitors of BACE-1 such as thiazolidinediones, rosiglitazone, pioglitazone, Sc7 and tartaric acid are available with poor pharmacological properties. 
 Therefore, a computational approach was undertaken to design novel inhibitors against human BACE-1 with good pharmacological properties. 
 CONCLUSION 
         Seven leads were obtained and among them, six were proposed as potential leads based on  XP GScore 
with better binding affinity and good  pharmacological properties compared with existing inhibitors. 
  
        Lead 1 with XP GScore -8.051Kcal/mol, would be intriguing for rational drug design against              
Alzheimer’s disease and would  be highly encouraging for future Alzheimer’s therapy if tested in animal 
models.                                                                                                                                                  
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Lead1 
XP GScore :  -5.081 
 lead2 
XP GScore :  -7.490 
Figure: 2  Six proposed leads for human BACE-1 
 Figure:3   Comparison   of  XP GScore between  leads and  published inhibitor.            
Figure:4   Docking  complex of lead ’1’ with human BACE-1.  
Figure:5   Interactions  of  lead ‘1’  with  human BACE-1 protein. 
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lead3 
XP GScore: -7.122 
 Figure: 1 Five existing inhibitors of  human BACE-1.  
Lead5 
XP GScore:  -6.843 
lead4 
XP GScore:  -6.996 
lead6 
XP GScore:  -6.834 
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